13-04-2016Print
USA’s Merck & Co (NYSE: MRK) and Japanese drugmaker Taiho, a subsidiary of Otsuka (TYO: 4768), have announced a co-promotion agreement in Japan for the cancer treatment pembrolizumab.
Merck has filed an application for approval in Japan for the immune checkpoint inhibitor (anti-PD-1 therapy). Under the agreement, Taiho will co-promote pembrolizumab with the American giant, which will manufacture and distribute it.
Pembrolizumab is a humanized…
This article is accessible to registered users, to continue reading pleaseregister for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user pleaselogin. If your trial has come to an end, you cansubscribe here.
Free
7 day trial access
• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.
£820
or £77 per month
•不受限制地访问Pharma和Biotech中的行业领先新闻，评论和分析。
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
•制药和生物技术中的关键事件的每日综述。
• Monthly in-depth briefings on Boardroom appointments and M&A news.
•从具有成本效益的年度套餐或灵活的每月订阅中选择。
Sanofi Aventis英国董事长
BiotechnologyDeals免疫学日本Keytruda许可Merck & CoOncology大自然pembrolizumabRegulationTaiho Pharmaceuticals
